Acad9 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ACAD9 - Acyl-CoA dehydrogenase family member 9 |
|---|
| Gene Symbol | ACAD9 |
| Full Name | Acyl-CoA dehydrogenase family member 9 |
| Chromosomal Location | 3q21.3 |
| NCBI Gene ID | 28976 |
| OMIM | 611103 |
| Ensembl ID | ENSG00000177646 |
| UniProt ID | Q70947 |
| Associated Diseases | Mitochondrial complex I deficiency |
This section provides a comprehensive overview of the gene/protein and its role in the nervous system and neurodegenerative diseases.
The ACAD9 gene (Acyl-CoA Dehydrogenase Family Member 9) encodes a mitochondrial protein essential for the assembly and function of mitochondrial complex I (NADH:ubiquinone oxidoreductase), the largest complex of the electron transport chain. ACAD9 functions as a scaffolding protein that facilitates the proper assembly of complex I subunits.
ACAD9 plays a critical role in mitochondrial complex I biogenesis:
- Acts as an assembly factor for complex I
- Interacts with other assembly factors (NDUFAF1, NDUFAF2, NDUFAF4)
- Required for the incorporation of multiple core subunits
- Helps stabilize intermediate assembly complexes
While structurally related to acyl-CoA dehydrogenases:
- Does not have significant dehydrogenase activity toward fatty acids
- Functions primarily as a structural/assembly protein
- Binds FAD (flavin adenine dinucleotide) as a cofactor
- Required for proper folding of complex I modules
Biallelic mutations in ACAD9 cause mitochondrial complex I deficiency:
- Severe metabolic encephalopathy
- Lactic acidosis
- Developmental delay
- Hypotonia
- Failure to thrive
- Often fatal in childhood
Common manifestations include:
- Encephalomyopathy
- Cardiomyopathy
- Liver dysfunction
- Recurrent infections
- Movement disorders
ACAD9 deficiency can present as Leigh syndrome:
- Subacute necrotizing encephalomyelopathy
- Characteristic MRI findings
- Progressive neurological deterioration
- Metabolic crisis episodes
- Highest expression: heart, skeletal muscle, brain
- Moderate expression: liver, kidney
- Lower expression in other tissues
- Cerebral cortex
- Cerebellum
- Brainstem
- Basal ganglia
ACAD9 interacts with:
- NDUFAF1: Complex I assembly factor
- NDUFAF2: Alternative complex I assembly factor
- NDUFAF4: Assembly factor for intermediate modules
- Complex I subunits: Various core and accessory subunits
- FAD: Flavin cofactor binding
- Genetic testing for ACAD9 mutations
- Biochemical testing (complex I activity)
- Muscle biopsy
- MRI brain imaging
- Metabolic screening
- No approved disease-modifying therapy
- Supportive care
- CoQ10 supplementation (variable response)
- Riboflavin supplementation
- Physical therapy
- Seizure management
- Variable depending on mutation severity
- Early-onset forms often severe
- Some patients survive into adulthood
Current research areas include:
- Understanding ACAD9 function in complex I assembly
- Developing small molecules to enhance assembly
- Gene therapy approaches
- Biomarker development for monitoring disease progression
The study of Acad9 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- ACAD9 mutations cause mitochondrial complex I deficiency (2010)
- Complex I assembly factors in mitochondrial disease (2015)
- ACAD9 function in oxidative phosphorylation (2017)
- Mitochondrial disease diagnostics (2019)
- Therapeutic approaches for complex I disorders (2020)
- Riboflavin supplementation in mitochondrial disease (2021)
- Gene therapy for mitochondrial complex I deficiency (2022)
- Mitochondrial dynamics in neurodegeneration (2023)